73 Papers
407 Citations
Maria Duca is an academic researcher from Centre national de la recherche scientifique. The author has contributed to research in topics: RNA & Biology. The author has an hindex of 15, co-authored 60 publications. Previous affiliations of Maria Duca include Academy of Sciences of Moldova & French Institute of Health and Medical Research.
Chat about Author
Papers
The triple helix: 50 years later, the outcome
Maria Duca,Pierre Vekhoff,Pierre Vekhoff,Kahina Oussedik,Kahina Oussedik,Ludovic Halby,Ludovic Halby,Paola B. Arimondo,Paola B. Arimondo +8 more
TL;DR: The state of art of the triplex-based anti-gene strategy 50 years after the discovery of such a structure is reported, and the importance of the actual applications and the main challenges that the authors still have ahead of us are shown.
343
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents
A Di Giorgio,Maria Duca +1 more
TL;DR: This review reports the most relevant examples of synthetic compounds bearing sufficient selectivity to envisage clinical studies and future therapeutic applications with a particular attention for the main strategies that can be undertaken toward the improvement of selectivity and biological activity.
Targeting DNA base pair mismatch with artificial nucleobases. Advances and perspectives in triple helix strategy
TL;DR: The contribution of the chemists' community to the development and application of triple helix strategy by using artificial nucleic acids, particularly for the recognition of DNA sequences incorporating base pair inversions is described.
61
Oncogenic MicroRNAs Biogenesis as a Drug Target: Structure-Activity Relationship Studies on New Aminoglycoside Conjugates.
Duc Duy Vo,Thi Phuong Anh Tran,Cathy Staedel,Cathy Staedel,Rachid Benhida,Fabien Darfeuille,Fabien Darfeuille,Audrey Di Giorgio,Maria Duca +8 more
TL;DR: The synthesis and biological evaluation of new small-molecule drugs that target oncogenic miRNAs production and inhibit proliferations of adenocarcinoma gastric cancer (AGS) cells overexpressing these miRNA-372 and -373, thus representing promising leads for future drug development.
48